Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol
- 1 May 2003
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (5) , 1513-1517
- https://doi.org/10.2337/diacare.26.5.1513
Abstract
OBJECTIVE—To assess the effect of insulin resistance and the benefit of the fibrate, gemfibrozil, on the incidence of major cardiovascular events in subjects with low HDL cholesterol and a broad range of triglyceride values who participated in the Veterans Affairs High Density Lipoprotein Intervention Trial (VA-HIT). RESEARCH DESIGN AND METHODS—This intention-to-treat analysis, specified as a secondary objective in VA-HIT, determined using Cox proportional hazards models the 5-year combined incidence of nonfatal myocardial infarction, coronary heart disease (CHD) death, or stroke in relation to the presence or absence of insulin resistance (defined by the highest tertile of the homeostasis model assessment of insulin resistance, HOMA-IR) in conjunction with lower and higher levels of HDL cholesterol and triglycerides. The study population consisted of 2,283 men with known coronary heart disease (CHD), treated with either placebo or gemfibrozil, who could be subdivided into groups with diabetes with or without insulin resistance, with no diabetes but insulin resistance, and with neither diabetes nor insulin resistance. RESULTS—With insulin resistance there was a significantly higher relative risk (RR) of a cardiovascular event both with diabetes (RR of 1.62 with 95% CI of 1.28–2.06) and without diabetes (RR of 1.43 with 95% CI of 1.03–1.98) than without insulin resistance. Throughout both lower and higher ranges of HDL cholesterol and triglycerides, the rate of new cardiovascular events and the reduction of events with gemfibrozil was greater in subjects with insulin resistance than without, despite the finding that an increase in HDL cholesterol and a decrease in triglycerides with gemfibrozil was less with insulin resistance than without insulin resistance. CONCLUSIONS—Results show that in VA-HIT the occurrence of a new cardiovascular event and the benefit of fibrate therapy was much less dependent on levels of HDL cholesterol or triglycerides than on the presence or absence of insulin resistance.Keywords
This publication has 18 references indexed in Scilit:
- Fibrates and coronary heart disease reduction in diabetesCurrent Opinion in Endocrinology, Diabetes and Obesity, 2002
- Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein CholesterolNew England Journal of Medicine, 1999
- Insulin Resistance Syndrome Predicts Coronary Heart Disease Events in Elderly Nondiabetic MenCirculation, 1999
- The veterans affairs high-density lipoprotein intervention trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterolThe American Journal of Cardiology, 1996
- Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrationsJournal of Clinical Endocrinology & Metabolism, 1996
- Hyperinsulinemia as an Independent Risk Factor for Ischemic Heart DiseaseNew England Journal of Medicine, 1996
- Some Coronary Risk Factors Related to the Insulin Resistance Syndrome and Treatment With GemfibrozilCirculation, 1995
- Rationale and design of the Department of Veterans Affairs high-density lipoprotein cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterolThe American Journal of Cardiology, 1993
- Altering Triglyceride Concentrations Changes Insulin-Glucose Relationships in Hypertriglyceridemic Patients: Double-Blind Study With Gemfibrozil With Implications for AtherosclerosisDiabetes Care, 1991
- Risk Factors for Coronary Artery Disease in Healthy Persons with Hyperinsulinemia and Normal Glucose ToleranceNew England Journal of Medicine, 1989